Categories
Business Featured News Technology

The pharmaceutical contract research services market, is anticipated to be worth USD 59 billion by 2030, growing at an annualized rate of over 10%, claims Roots Analysis

Customized services, reduced cost and access to advanced technologies offered by contract research service providers, have prompted a number of pharmaceutical companies to outsource their research operations

 

London

 

Roots Analysis has announced the addition of “Pharmaceutical Contract Research Services Market, 2021-2030” report to its list of offerings.

 

Majority of the small companies as well as a few mid to large sized players, do not have the required capital or experience to undertake the development programs by themselves. Moreover, the costs associated with idle capacity for such specialized facilities are also high. As a result, the extent of outsourcing activities has considerably increased over the past few years.

 

To order this 290+ page report, which features 95+ figures and 130+ tables, please visit this link

 

Key Market Insights 

 

Presently, more than 520 players claim to offer contract research services

Nearly 70% of the players provide contract research services for conducting clinical trials, followed by those offering services concerning regulatory affairs management (49%). It is worth mentioning that 41 service providers claim to have the required expertise to serve as one-stop-shops to cater to the needs of various pharmaceutical firms.

 

Partnership activity within this domain has grown significantly, since 2018

In the last three years, more than 190 agreements were inked by the pharmaceutical contract research service providers, with maximum activity being reported in 2020. Majority of the instances were related to acquisitions (20%), clinical trial agreements (18%), R&D agreements (14%), and research agreements (12%).

 

Close to 50 mergers and acquisitions were established in this domain, during the period 2018-2021

It was observed that majority of the deals were intracontinental (76%), involving participants from the same countries. Geographical consolidation and service portfolio expansion were observed to the major key value drivers of M&A activity in this domain. This was followed by instances of service portfolio addition and geographical expansion.

 

At present, companies offering clinical stage services represent majority of the market share (in terms of sales revenues)

By 2030, the pharmaceutical contract research market in North America is estimated to be worth USD 29 billion, representing an annualized growth rate of 9.7%. It is worth mentioning that the market in Asia-pacific is anticipated to grow at a relatively faster pace, during the forecast period.

.

 

To request a sample copy / brochure of this report, please visit this link

 

Key Questions Answered

  • Who are the leading players offering contract research services for small molecules?
  • Which partnership models are commonly adopted by stakeholders engaged in pharmaceutical contract research services market?
  • What are the key value drivers of the merger and acquisition activity observed within pharmaceutical contract research services market?
  • What are the likely future trends in contract research services market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What is the total cost of ownership required to set up a pharmaceutical contract research organization?

 

The USD 59 billion (by 2030) financial opportunity within the pharmaceutical contract research service providers market has been analyzed across the following segments:

  • Scale of Operation
  • Discovery
  • Preclinical
  • Clinical

 

  • Target Therapeutic Area
  • Oncological Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Inflammatory Disorders
  • Cardiovascular Disorders
  • Dermatological Disorders
  • Ophthalmic Diseases
  • Respiratory Disorders

 

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia- Pacific
  • Middle East
  • North Africa
  • Latin America

 

 

The report also features detailed profiles of key players (listed below); each profile features a brief overview of the company, its financial information (if available), information on the services offered and an informed future outlook.

  • Albany Molecular Research (AMRI)
  • BioDuro
  • BOC Sciences
  • Catalent Pharma
  • Charles River Laboratories
  • ChemDiv
  • Covance
  • Medpace
  • QPS
  • Concept Life Sciences
  • Evotec
  • ChemPartner
  • Pharmaron
  • Syngene
  • Torrent Pharma
  • WuXi AppTec

 

For additional details, please visit

https://www.rootsanalysis.com/reports/pharmaceutical-contract-research-services-market.html

or email [email protected]

 

You may also be interested in the following titles:

  1. Biospecimen Contract Research Services Market, 2021–2030
  2. Biopharmaceutical CROs Market, 2021-2030
  3. Cell and Gene Therapy CROs Market, 2021-2030

 

 

 

Contact:
Ben Johnson

+1 (415) 800 3415

[email protected]

 

 

 

Categories
Business News Technology

Currently, more than 220 players, across the globe, claim to have the necessary expertise to offer contract manufacturing services (drug substance and drug product) for various types of biologics, claims Roots Analysis

Biologics production is a complex and capital-intensive process fraught with a wide range of challenges including the rate of attrition of pipeline drugs / therapies, prolonged development timelines, complex molecular structure, current facility limitations and capacity constraints, and safety and efficacy-related issues. Given the technical and operational challenges outlined above, an increasing number of drug developers have demonstrated the preference to outsource various parts of their biologics manufacturing operations.

 

To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this link

 

The USD 32.4 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing  market has been analyzed across the following segments:

  • Commonly outsourced business operations
  • API
  • FDF

 

  • Types of Expression Systems Used
  • Mammalian
  • Microbial
  • Others

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Company Size
  • Small
  • Mid-sized
  • Large / Very Large

 

  • Types of Biologics Manufactured
  • Antibody Therapeutics
  • Vaccines
  • Cell Therapies
  • Other Biologics

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa

 

The Biopharmaceutical Contract Manufacturing Market, (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • AGC Biologics
  • Boehringer Ingelheim
  • Catalent
  • Cytiva (GE Healthcare)
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Kemwell Biopharma
  • Lonza
  • Luina Bio
  • Novasep
  • Olon
  • Patheon
  • Piramal Pharma Solutions
  • Takara Bio
  • WuXi AppTec (WuXi Biologics)

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Competitive Landscape
  4. Manufacturing Facilities of Biopharmaceutical Contract Manufacturing Organizations (CMOs)
  5. Biopharmaceutical Contract Manufacturing in North America
  6. Biopharmaceutical Contract Manufacturing in Europe
  7. Biopharmaceutical Contract Manufacturing in Asia-Pacific and the Rest of the World
  8. Niche Biopharmaceutical Sectors
  9. Case Study: Outsourcing of Biosimilars
  10. Case Study: Comparison of Small and Large Molecules Drugs / Therapies
  11. Case Study: In-House Manufacturing
  12. Make Versus Buy Decision Making Framework
  13. Big Pharma Initiatives
  14. Partnerships and Collaborations
  15. Mergers and Acquisitions
  16. Recent Expansions
  17. Recent Developments
  18. Capacity Analysis
  19. Demand Analysis
  20. Market Sizing and Opportunity Sizing
  21. Swot Analysis
  22. Future of the Biopharmaceutical CMO Market
  23. Survey Analysis
  24. Interview Transcripts
  25. Appendix 1: Tabulated Data
  26. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Categories
Business Featured Market

The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry.

To order this 750+ page report, please visit this https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Key Inclusions

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
  • An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
  • An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region
  • North America
  • Europe
  • Asia-Pacific

 

To request sample pages, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html

 

Key Questions Answered

  • Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
  • What is the global demand for biologics-based therapies?
  • What are the major recent developments (such as partnerships and expansions) in this industry?
  • What kind of partnership models are commonly adopted by stakeholders in this domain?
  • What is the current, installed contract manufacturing capacity for biologics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
  2. Antibody Contract Manufacturing Market, 2020-2030
  3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
  4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Business Market News

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX’Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Competitive Landscape
  4. Biopharmaceutical Contract Manufacturing in North America
  5. Biopharmaceutical Contract Manufacturing in Europe
  6. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World
  7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

 

  1. Case Study: Outsourcing of Biosimilars
  2. Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies

 

  1. Case Study on In-House Manufacturing
  2. Collaborations
  3. Recent Developments
  4. Capacity Analysis

 

  1. Demand Analysis

 

  1. Market Forecast

 

  1. SWOT Analysis

 

  1. Future of The Biopharmaceutical CMO Market

 

  1. Survey Analysis

 

  1. Interview Transcripts

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Categories
Business Market Technology

The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

 

Roots Analysis is pleased to announce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.

 

The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
  • An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

The report also features detailed transcripts of discussions held with the following experts:

  • Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • Christian Bailly, Director of CDMO, Pierre Fabre
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • Kevin Daley, Director Pharmaceuticals, Novasep
  • Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • Nicolas Grandchamp, R&D Leader, GEG Tech
  • Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • Sebastian Schuck, Head of Business Development, Wacker Biotech
  • Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
  • Tim Oldham, Chief Executive Officer, Cell Therapies

 

Key companies covered in the report

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX’Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

For more information please click on the following link:

Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030

 

Other Recent Offerings

  1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
  2. Antibody Contract Manufacturing Market, 2020-2030
  3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
  4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

 

Categories
Featured Market

The site management organizations (SMO) market is projected to grow at an annualized rate of ~10% during the period 2021-2035, claims Roots Analysis

The rapidly growing clinical pipeline and challenges associated with the conduct of clinical trials in a cost and time effective manner, has presented lucrative opportunities for service providers with expertise in clinical trial site management

 

Roots Analysis has announced the addition of “Site Management Organizations (SMO) Market, 2021 – 2035” report to its list of offerings

 

In recent years, drug / device developers have demonstrated a preference to continue relying on SMOs for conducting clinical trials in order to significantly optimize trial cost and research timelines. Driven by the steady growth in clinical research activity and inherent benefits offered by SMOs, the market opportunity for such players is projected to grow at a significant pace in the foreseen future.

 

To order this 270+ page report, which features 95+ figures and 120+ tables, please visit

https://www.rootsanalysis.com/reports/site-management-organizations-market.html

 

Key Market Insights

 

Around 250 companies across the world claim to offer clinical trial site management services

Majority (43%) of the industry stakeholders are headquartered in North America, followed by those based in Asia-Pacific (32%) and Europe (19%). In addition, 25% of the companies engaged in this domain offer site management services across the globe, followed by those providing services in Asia-Pacific (23%).

 

200+ partnerships were established in this domain, during the period 2016-2021

Service alliances (26%) and clinical trial agreements (23%) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Nearly 65% of the deals in this domain were established after 2018, with the maximum activity being reported in 2021 (56).

 

~USD 1 billion invested in various domain focused initiatives, since 2015

Maximum number of funding instances (21%) were reported in 2021, amounting to USD 614 million in capital investments. A significant number of funding instances (43%) were venture capital rounds, followed by instances of other equity (29%) and grants (7%).

 

Till 2035, annual demand for clinical trial study participants is expected grow at a CAGR of 8.2%

Currently, North America and Asia-Pacific hold the majority share of the overall demand for clinical trial study participants (60%). By 2035, the demand for patients in clinical trial studies is projected to reach 25 million. Further, currently, the highest demand is generated via phase III trials (43%), followed by phase IV studies (38%).

 

North America and Europe are anticipated to capture close to 65% of the market share, by 2035

In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (9%) in the long term. Further, in 2035, the majority share (~45%) of clinical trial site management revenues is likely to be generated from trials focused on phase III evaluation of clinical studies.

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/site-management-organizations-market.html

 

Key Questions Answered

  • Who are the leading players engaged in the clinical trial site management domain?
  • What is the relative competitiveness of different site management organizations?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What is the capital investments trend in the site management organizations domain?
  • Which are the most active clinical trial centers?
  • What are the major market trends and driving factors that are likely to impact the growth of site management organizations market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

The financial opportunity within the SMOs market has been analyzed across the following segments:

 

  • Therapeutic Areas
  • Oncological Disorders
  • CNS Disorders
  • Infectious Diseases
  • Respiratory Disorders
  • Cardiovascular Diseases
  • Endocrine Disorders
  • Gastrointestinal Disorders
  • Musculoskeletal Diseases
  • Immunological Disorders
  • Others

 

  • Trial Phases
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

 

  • Clinical Trial Components
  • Site Management
  • Onsite Monitoring
  • Project Management
  • Data Management
  • Regulatory Affairs
  • Logistics
  • Quality Control
  • Others

 

  • Types of Interventions
  • Therapeutics
  • Devices
  • Surgical Procedure

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MENA
  • Rest of the World

 

The report also features inputs from eminent industry stakeholders, according to whom, complexities associated with clinical trial processes and increasing clinical pipeline will drive the growth of the third-party service providers, such as SMOs, engaged in this domain, in the coming future. The report includes detailed transcripts of discussions held with the following experts:

 

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its site management service portfolio, recent developments and an informed future outlook.

  • FOMAT Medical Research
  • Parexel
  • Pharm-Olam
  • Veristat
  • WCCT Global
  • Worldwide Clinical Trials
  • CROMSOURCE
  • Fidelis Research
  • Scandinavian CRO
  • TFS HealthScience
  • Trialbee
  • CMIC
  • George Clinical
  • Tigermed
  • Veeda Clinical Research

 

For additional details, please visit

https://www.rootsanalysis.com/reports/site-management-organizations-market.html

or email [email protected]

 

You may also be interested in the following titles:

  1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
  2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
  3. Clinical Trial Planning and Design Services Market: Industry Trends and Global Forecasts, 2021-2030
  4. Biospecimen Contract Research Services Market: Industry Trends and Global Forecast, 2021-2030
  5. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030

 

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]

 

 

 

 

Categories
Business COVID Market News

Non-invasive Aesthetic Treatment Market Scope Assessment 2030

Non-invasive Aesthetic Treatment: Popular Method for Cosmetic Procedures

  • Aging is considered a serious aesthetic issue. Signs of aging include wrinkles around eyes or lips, age spots, and sagging skin.
  • There used to be few options for turning back the clock without undergoing surgery. However, currently, one can soften the effects of time on the face with several non-surgical cosmetic procedures.
  • Non-invasive aesthetic treatment has gained popularity in the past few years. Common procedures include Botox, dermal fillers, spider vein treatment, and chemical peels.
  • Presently, patients prefer non-invasive aesthetic treatment methods due to benefits such as minimal downtime, no scars, lower cost, and reduced risk of complications

For More Industry Insight, Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77190

Key Drivers and Restraints of Global Non-invasive Aesthetic Treatment Market

  • Increase in geriatric population, rise in adoption of non-invasive aesthetic treatment, and surge in beauty consciousness among consumers are the major drivers of the global non-invasive aesthetic treatment market
  • According to the American Society of Plastic Surgeons, the number of invasive cosmetic procedures dropped 6% from 2000 to 2016 in the U.S., while non-invasive and minimally invasive procedures witnessed 180% increase during that same period
  • Availability of technologically advanced & user-friendly products and increase in demand for aesthetic treatments among men are the key factors fueling the growth of the global non-invasive aesthetic treatment market
  • Moreover, increase in the number of approved products and high efficiency & safety offered by some products boost the growth of the global non-invasive aesthetic treatment market

Pre Book Non-invasive Aesthetic Treatment Market Report at – https://www.transparencymarketresearch.com/checkout.php?rep_id=77190&ltype=S

Clinical Risks and Complications Associated with Medical Aesthetic Procedures Hamper Market Growth

  • Clinical risks and complications associated with medical aesthetic procedures are factors projected to hamper the growth of the global market
  • Increase in availability and adoption of alternative beauty and cosmetic products are also anticipated to hamper the growth of the global non-invasive aesthetic treatment market

Injectables to be Dominant Segment

  • In terms of procedure, the global non-invasive aesthetic treatment market can be classified into injectables, skin rejuvenation, and others
  • The injectables segment accounted for major market share during the forecast period due to faster treatment, quick results, and efficiency in treating a range of blemishes
  • The skin rejuvenation segment is expected to expand at a higher CAGR during the forecast period owing to rise in popularity of procedures and better efficiency in restoring patient’s youthful appearance through skin alterations
  • The injectables segment can be split into botulinum toxin, calcium hydroxylapatite, hyaluronic acid, polymer filler, and collagen
  • The skin rejuvenation segment can be segregated into chemical peel, laser skin resurfacing, and photorejuvenation

Request Analysis of COVID-19 Impact on Non-invasive Aesthetic Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77190

Clinics & Medical Spas to be Highly Lucrative Segment

  • Based on end-user, the global non-invasive aesthetic treatment market can be divided into hospitals, clinics & medical spas, and others
  • The hospitals segment dominated the global market in 2019 due to availability of technologically advanced devices, trained staff, and skilled professionals to perform aesthetic procedures

North America to Lead Global Non-invasive Aesthetic Treatment Market

  • In terms of region, the global non-invasive aesthetic treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global non-invasive aesthetic treatment market in 2019 due to increase in number of cosmetic procedures, high disposable income of consumers, and rise in demand for cosmetic procedures among adults and the geriatric population in the region.
  • According to the American Society of Plastic Surgeons, 15.9 million cosmetic minimally-invasive procedures were performed in the U.S. in 2018, which was 2% more than in 2017
  • Asia Pacific is likely to be a highly lucrative market during the forecast period owing to increase in awareness about aesthetic treatments, growing medical tourism, and rise in focus of multinational companies in the region

Key Players Operating in Global Non-Invasive Aesthetic Treatment Market

 Key players operating in the global market are:

  • Galderma S.A.
  • Alma Lasers
  • Allergan
  • Cynosure (a wholly owned subsidiary of Hologic, Inc.)
  • El.En. S.p.A.
  • Johnson & Johnson
  • Syneron Candela
  • Merz Pharma
  • Lumenis
  • Solta Medical

Request for Discount – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=77190

More Trending Reports by Transparency Market Research:

Heat Therapy Market: Heat therapy market has been categorized into musculoskeletal disorder, sports medicine, post operative therapy, mastitis, chronic pain management, injury, and others. The musculoskeletal disorder segment held a major share of the global heat therapy market in 2020.

Dengue Vaccines Market: The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda – a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/

Categories
Business COVID Market News

Surgical Sutures Market Future Adoption Overview 2025

The consolidated competitors landscape of global surgical sutures market is set witness a decent CAGR (Compound Annual Growth Rate) over the forecast period of 2017-2025, creating opportunities for market players worth USD 5 billion. Players would hurry to make the most of these untapped opportunities set to merge over the market landscape. Some of the most notable players include Cardinal Health, Medela AG, Integra LifeSciences Corporation, Acelity L.P. Inc., and Smith and Nephew plc, among others. Here, it is worth noting that in the year 2015 about 65% of the total market share was held by top 5 companies.

Get Exclusive PDF Sample Copy Of This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19172

A Transparency Market Research (TMR) market study report on global surgical sutures market explains that factors such as increase in incidence of trauma, hernia and conditions related to breast, skin and soft tissue is fueling the market on the trajectory of growth. Besides, a growing prevalence of disorders relating to musculoskeletal system is adding to this growth trajectory.

For More Industry Insight, Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19172

It is worth noting that a swift rise in the aged demographics is also driving the global surgical sutures market over the forecast period as this demographic is particularly susceptible to slow healing wounds, surgeries and chronic diseases that sometime need certain procedures to be done surgically. Some statistics might add to the overall picture in this regard. One, worldwide, the global population will see a large number of 2 billion people aged 60 and above by the year 2050. Additionally, one in every four people in North America, and in Europe will be aged 65 and above. This ratio would be one in every sic on the global level.

Buy Surgical Sutures Market Report at – https://www.transparencymarketresearch.com/checkout.php?rep_id=19172&ltype=S

It is worth mentioning here that history was created in the year 2018, when demographics shifted dramatically – number of aged surpassing the number of children. The age bracket for former was 65 and above and for latter it is five and below.

North America to Dominate the Global Surgical Sutures Market over the Forecast Period

Request Analysis of COVID-19 Impact on Surgical Sutures Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=19172

High geriatric population – one in every four by 2050 in the 65 and above age bracket – and rise in demand for surgeries owing to age, lifestyle issues and rise in chronic diseases is helping the North American region to chart impressive figures over the forecast period. There is indeed a massive increase in the incidence of cardiovascular diseases (CVD). Also, chronic diseases in the United States of America are seeing a high incidence with six in every ten people suffering from one and sour in every ten people suffering from at least two chronic diseases. An advances medical environment, high disposable incomes and a robust reimbursement infrastructure also works in favor of the North American Region.

Request for Discount – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=19172

More Trending Reports by Transparency Market Research:

Heat Therapy Market: Heat therapy market has been categorized into musculoskeletal disorder, sports medicine, post operative therapy, mastitis, chronic pain management, injury, and others. The musculoskeletal disorder segment held a major share of the global heat therapy market in 2020.

Dengue Vaccines Market: The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda – a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/

Categories
Business COVID Market News

Exoskeleton Market Growth, Analysis, And Research, Trends 2025 | TMR Study

Exoskeletons are wearable devices which are used to enhance the physical competency of the wearer. By overcoming the physical limitations, these wearable machines assist limb movements with better strength and help the wearer perform various tasks. Exoskeletons can be powered with electric motors, actuators, pneumatics, sensors, hydraulics, levers or a combination of technologies or it can be completely passive. The use of exoskeletons to improve the quality of life of the people with mobility disorders in the medical field is on the rise. Usually, exoskeletons used in the medical field are modular and lightweight which allows the user to independently put on and remove each piece smoothly. Further, market players are coming up with exoskeletons which can be utilized by patients with spinal cord injury or rehabilitation of stroke. Exoskeleton devices are also used in mobility aids and rehabilitation patients with physical and neurological disorders. Some military class exoskeletons are powered by fuel cells, and internal combustion engine or batteries which helps military personnel to carry heavy objects and also supports and protects the human body.

For More Industry Insight, Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36833

Growth in demand from the healthcare industry and significant advancements in robotic technologies are some of the key factors expected to drive the exoskeletons market over the forecast period from 2017 to 2025. Adoption of exoskeletons in the healthcare industry to treat and cure disorders such as paralysis, muscular dystrophy, and general fatigue is gaining momentum. Furthermore, use of exoskeleton devices are anticipated to grow to help the aging population especially in countries such as China and Japan. According to statistics provided in the World Population Ageing 1950-2050 report by Population Division, DESA of the United Nations, China and Japan have 12 million and 5 million people respectively of age 80 years and above. Further, in 2050, these figures are expected to reach 99 million and 17 million for China and Japan individually. Owing to this factor, expenses incurred on elder care are likely to increase, which can be reduced with the help of exoskeleton devices. Therefore, adoption of exoskeleton devices to help the elderly population with their routine activities is projected to rise in the coming years. Major technological breakthroughs by OEMs in robotic technologies are also expected to give a push to the exoskeleton market. In March 2016, Japanese multinational, Panasonic Corporation launched a pair of exoskeleton suits built with new robotic technology to be used for industrial purposes, and to help disabled people. The suits come with a motor equipped robot, created from sensors and advanced motion control technologies. High costs associated with devices and stringent government regulations pertaining to the use of exoskeletons in the medical sector are likely to be limiting factors for market growth. Implementation of exoskeletons and associated technologies in commercial health insurance plans by insurance providers presents huge opportunity for market growth.

Pre Book Exoskeleton Market Report at – https://www.transparencymarketresearch.com/checkout.php?rep_id=36833&ltype=S

The market is segmented on the basis of component, type, application, and region. On the basis of component, the global exoskeleton market is subdivided into hardware and software. By type, the market is classified into full body exoskeleton, lower body exoskeleton, and upper body exoskeleton. On the basis of application, the market is segmented into industrial, military, healthcare and others. Geographically, the global exoskeleton market is segmented into North America, Europe, Middle East & Africa, Asia Pacific (APAC), and South America. Expected strong adoption rate of exoskeleton devices in Asian countries to help aged population especially in China, Japan, and India, APAC region is expected to contribute to substantial revenue share during the forecast period.

Some of the key players in the global exoskeleton market are Cyberdyne Inc., Bionik Laboratories Corp., GOGOA Mobility Robots, Ekso Bionics, B-Temia Inc., Focal Meditech, DIH Technologies Corporation, ReWalk Robotics, Ottobock, and SuitX.

Request Analysis of COVID-19 Impact on Exoskeleton Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=36833

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request for Discount – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=36833

More Trending Reports by Transparency Market Research:

Heat Therapy Market: Heat therapy market has been categorized into musculoskeletal disorder, sports medicine, post operative therapy, mastitis, chronic pain management, injury, and others. The musculoskeletal disorder segment held a major share of the global heat therapy market in 2020.

Dengue Vaccines Market: The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda – a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/

Categories
Business COVID Market News

Cell Expansion Market Trends and Growth Factors Analysis 2016 – 2024

The cell expansion market features fragmented vendor landscape owing to a large number of key players operating in the market. Takara Bio, Inc., GE Healthcare, Corning Incorporated, Terumo Corporation, Lonza Group, Octane Biotech, Inc., Danaher Corporation (Pall Corporation), PeproTech, Inc., Eppendorf AG, Becton, Dickinson and Company, Merck Millipore (Merck KGaA), Cell Signaling Technology, Inc., STEMCELL Technologies, Bio-Techne (R&D Systems), are some of the key players in the global cell expansion market.

Get Exclusive PDF Sample Copy Of This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9037

According to TMR, the cell expansion market is likely to expand by exhibiting a striking CAGR of 14.70% during the forecast period from 2016 to 2024. The market initially had gained a revenue worth US$7.7 bn in 2015, which is further expected to increase up to US$26 bn by 2024.

For More Industry Insight, Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9037

The worldwide cell expansion market is increasing broad development fundamentally because of boundless predominance of constant ailments, which further expanding the requirement for utilization of cell expansion-based procedures. The inclination for regenerative prescriptions is likewise quick rising, which is enormously expected to move the worldwide cell expansion market’s development sooner rather than later. As more current cell-based treatments are presented, the quantity of patients who need to use the medicines increments, therefore making the market increase broad development. Finally, an ascent in biopharmaceuticals is another factor, which is probably going to foreshadow the worldwide cell expansion market to extend generously during the up and coming years.

Buy Cell Expansion Market Report at – https://www.transparencymarketresearch.com/checkout.php?rep_id=9037&ltype=S

Absence of Skilled Workforce in Underdeveloped Regions Dampens Growth

Surprising expense of cell expansion tasks could demoralize those having less extra cash to not decide on medicines that consolidate cell expansion-based procedures, along these lines limiting the market. This could very happen in a few economies for the most part situated in creating and immature districts of Asia Pacific and Latin America. Absence of talented workforce and cutting edge instrumentation in these locales is likewise known to generously confine the worldwide cell expansion market. By the by, a rising mindfulness about the presence of cell-expansion procedures is expanding premium levels appeared by players to develop in the market. This mindfulness can eventually contribute towards early analysis of a few endless illnesses, subsequently counterbalancing the restrictions during the up and coming years.

Request Analysis of COVID-19 Impact on Cell Expansion Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=9037

This information is encompassed in the report by TMR, titled, “Cell Expansion Market (Cell Type – Human Stem Cells, Human Differentiated Cells, and Animal Cells; Product – Instruments, Consumables, and Disposables; End User – Hospitals, CMO & CRO, Biotechnology & Pharmaceutical Companies, and Academic & Research Institutes) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.”

Request for Discount – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=9037

More Trending Reports by Transparency Market Research:

Heat Therapy Market: Heat therapy market has been categorized into musculoskeletal disorder, sports medicine, post operative therapy, mastitis, chronic pain management, injury, and others. The musculoskeletal disorder segment held a major share of the global heat therapy market in 2020.

Dengue Vaccines Market: The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda – a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/